One of only two FDA-approved ALS therapeutics, edaravone, has been shown to increase RET and GFRα1 protein levels, and increase AKT and ERK1/2 activation in MNs derived from ALS-patient iPSCs [24]. Here, MAPK3 is linked to amyotrophic lateral sclerosis.